Zentalis Pharmaceuticals (ZNTL) Net Equity Issued and Repurchased (2019 - 2022)

Zentalis Pharmaceuticals' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $48.6 million for Q4 2022.

• In Q4 2022, Net Equity Issued and Repurchased rose 398.72% year-over-year to $48.6 million; the TTM figure through Sep 2024 stood at $48.6 million (down 79.12% YoY), while the FY2025 annual figure was $5.4 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q4 2022 stood at $48.6 million, down from $184.3 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $184.3 million in Q2 2022, with the low at -$141.7 million in Q4 2020.
• The 4-year median for Net Equity Issued and Repurchased is $65.3 million (2019), against an average of $62.6 million.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased climbed 14.51% in 2021, then soared 398.72% in 2022.
• Zentalis Pharmaceuticals' Net Equity Issued and Repurchased stood at $81.9 million in 2019, then slumped by 272.98% to -$141.7 million in 2020, then surged by 106.88% to $9.8 million in 2021, then jumped by 398.72% to $48.6 million in 2022.
• Business Quant data shows ZNTL's Net Equity Issued and Repurchased at $48.6 million in Q4 2022, $184.3 million in Q2 2022, and $9.8 million in Q4 2021.